Prevents postoperative nausea and vomiting (PONV). Sold as Emend, Cinvanti, Aponvie, Aprepitant. Every FDA application for this active ingredient: 5 branded and 5 generic.
As of Nov 13, 2026, FDA lists 10 applications for Aprepitant (sold as Emend, Cinvanti, Aponvie and others), first approved Mar 26, 2003, with 6 new uses approved and 0 published complete response letters.
| Product | Part | Spending, 2024 | Change | Beneficiaries |
|---|---|---|---|---|
| Cinvanti | Part B | $42.3M | +5% | 40,602 |
| Aprepitant | Part D | $8.1M | -7% | 5,483 |
| Cinvanti | Part D | $289K | +104% | 149 |
| Emend | Part D | $123K | +100% | 15 |
| Aprepitant | Part B | $1K | -50% | 0 |
| Shortage | Status | First posted | Updated |
|---|---|---|---|
| Aprepitant Oral Powder for Suspension | To Be Discontinued | Apr 8, 2026 | Apr 8, 2026 |
| Approved | Application | Sponsor | Supplements | Marketing |
|---|---|---|---|---|
| Mar 26, 2003 | EmendNDA 21549 · New molecular entity | Msd | 21 | Marketed |
| Sep 24, 2012 | AprepitantANDA 90999 | Sandoz | 6 | Marketed |
| Dec 17, 2015 | EmendNDA 207865 · New dosage form | Msd Merck Co | 3 | Discontinued |
| Oct 12, 2017 | AprepitantANDA 207777 | Glenmark Speclt | 1 | Marketed |
| Nov 9, 2017 | CinvantiNDA 209296 · New dosage form | Heron Theraps Inc | 4 | Marketed |
| Oct 21, 2020 | AprepitantANDA 211835 | Torrent | 1 | Marketed |
| Sep 16, 2022 | AponvieNDA 216457 · New indication | Heron Theraps Inc | 1 | Marketed |
| Mar 5, 2026 | AprepitantANDA 218851 | Mylan | 0 | Discontinued |
| Jun 16, 2026 | AprepitantNDA 218754 · New formulation or manufacturer | Azurity | 0 | Marketed |
| — | AprepitantANDA 216976 | Mylan Pharmaceuticals Inc | 0 | Discontinued |
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number. Drugs@FDA
Sandoz